Aviso Wealth Management Has $247,000 Stake in Danaher Co. (NYSE:DHR)

Aviso Wealth Management boosted its holdings in Danaher Co. (NYSE:DHR) by 5.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 988 shares of the conglomerate’s stock after buying an additional 55 shares during the period. Aviso Wealth Management’s holdings in Danaher were worth $247,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Gilbert & Cook Inc. increased its holdings in Danaher by 4.9% in the fourth quarter. Gilbert & Cook Inc. now owns 1,830 shares of the conglomerate’s stock valued at $423,000 after purchasing an additional 86 shares during the last quarter. Accretive Wealth Partners LLC grew its position in shares of Danaher by 12.9% during the 4th quarter. Accretive Wealth Partners LLC now owns 3,632 shares of the conglomerate’s stock worth $840,000 after buying an additional 414 shares during the period. Gryphon Financial Partners LLC increased its stake in shares of Danaher by 19.1% in the 4th quarter. Gryphon Financial Partners LLC now owns 2,917 shares of the conglomerate’s stock valued at $675,000 after acquiring an additional 468 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Danaher by 1.6% in the 4th quarter. California State Teachers Retirement System now owns 1,122,816 shares of the conglomerate’s stock valued at $259,752,000 after acquiring an additional 17,475 shares during the period. Finally, Blue Whale Capital LLP boosted its stake in Danaher by 67.9% during the 4th quarter. Blue Whale Capital LLP now owns 201,500 shares of the conglomerate’s stock worth $46,615,000 after acquiring an additional 81,500 shares during the last quarter. 79.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the completion of the transaction, the director now directly owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last 90 days. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

DHR has been the subject of several recent analyst reports. Leerink Partners upped their target price on shares of Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI dropped their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Jefferies Financial Group initiated coverage on Danaher in a report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price on the stock. TD Cowen increased their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, Bank of America lifted their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Stock Performance

Shares of DHR stock opened at $275.44 on Friday. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $281.70. The company’s fifty day simple moving average is $270.23 and its 200-day simple moving average is $257.87. The firm has a market cap of $204.01 billion, a PE ratio of 46.68, a P/E/G ratio of 4.55 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The company’s revenue for the quarter was down 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.05 EPS. Equities research analysts expect that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.39%. Danaher’s dividend payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.